Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

PURPOSE: Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, the BTC patients received up to 6-8 cycles of 3-weekly GemCis; however, those without progression often receive more than 6-8 cycles. The clini...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res Treat
Päätekijät: Hyung, Jaewon, Kim, Bumjun, Yoo, Changhoon, Kim, Kyo-pyo, Jeong, Jae Ho, Chang, Heung-Moon, Ryoo, Baek-Yeol
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Korean Cancer Association 2019
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6639240/
https://ncbi.nlm.nih.gov/pubmed/30282446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.326
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia